Lorabid Related Published Studies
Well-designed clinical trials related to Lorabid (Loracarbef)
Improvement of otitis media with effusion after treatment of asthma with leukotriene antagonists in children with co-existing disease. [2005]
Penicillin V, loracarbef and clindamycin in tonsillar surface fluid during acute group A streptococcal pharyngotonsillitis. [2005]
A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis. [2000.06]
Loracarbef versus clarithromycin in children with acute otitis media with effusion. [1999.04]
Loracarbef versus phenoxymethylpenicillin in the treatment of recurrent streptococcal pharyngotonsillitis. [1997]
Twice-daily dosing of loracarbef 200 mg versus 400 mg in the treatment of patients with acute maxillary sinusitis. [1995.03]
Pharmacokinetic disposition of loracarbef in healthy young men and women at steady state. [1994.09]
Pharmacokinetics of loracarbef and interaction with acetylcysteine. [1992.09]
Loracarbef versus penicillin V in the treatment of streptococcal pharyngitis and tonsillitis. [1992.09]
Loracarbef vs. cefaclor in pediatric skin and skin structure infections. [1992.08]
Loracarbef (LY163892) vs. penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis. [1992.08]
Comparative United States and European trials of loracarbef in the treatment of acute otitis media. [1992.08]
Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis. [1992.06.22]
Loracarbef (LY163892) versus cefaclor in the treatment of bacterial skin and skin-structure infections in an adult population. [1992.06.22]
Loracarbef (LY163892) in the treatment of acute exacerbations of chronic bronchitis: results of U.S. and European comparative clinical trials. [1992.06.22]
Loracarbef (LY163892) versus amoxicillin-clavulanate in the treatment of bacterial acute otitis media with effusion. [1992.06]
Loracarbef (LY 163892) vs amoxicillin/clavulanate in bacterial maxillary sinusitis. [1992.05]
Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia. [1992.05]
Bactericidal titers of loracarbef (LY 163892) in serum and killing rates in volunteers receiving 400 versus 200 milligrams. [1992.03]
Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia. [1992.03]
Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis. [1992.03]
Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis. [1992.03]
Loracarbef versus cefaclor in the treatment of cystitis and asymptomatic bacteriuria. [1992.01]
Loracarbef (LY163892) versus cefaclor in the treatment of acute bacterial bronchitis. [1992.01]
Loracarbef versus penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis in adults. [1992.01]
Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media. [1991.05]
Loracarbef versus cefaclor in the treatment of urinary tract infections in women. [1991.04]
Well-designed clinical trials possibly related to Lorabid (Loracarbef)
Efficacy of sinus irrigation versus sinus irrigation followed by functional endoscopic sinus surgery. [1997.09]
Pharmacodynamic activity of five oral cephalosporins against Haemophilus influenzae. [1997.03]
Factors influencing outcome in children treated with antibiotics for acute otitis media. [1993.01]
Acute bacterial maxillary sinusitis: results of U.S. and European comparative therapy trials. [1992.06.22]
Other research related to Lorabid (Loracarbef)
The effect of four different types of diet on the bioavailability of loracarbef. [2007.10]
Serologically documented loracarbef (Lorabid)-induced immune thrombocytopenia. [2003.05]
Serum sickness-like reaction to cefaclor: lack of in vitro cross-reactivity with loracarbef. [1998.06]
A national collaborative study of the in vitro activity of oral cephalosporins and loracarbef (LY 163892). Australian Group for the Study of Antimicrobial Resistance (AGAR). [1997.02]
Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. [1996.03]
Penetration of loracarbef into the maxillary sinus: a pharmacokinetic assessment. [1996.03]
Acute interstitial nephritis associated with loracarbef therapy. [1995.12]
Revised disk diffusion interpretive criteria for cefaclor, loracarbef, cefprozil and cefixime when testing Haemophilus influenzae on haemophilus test medium. [1994.06]
Antimicrobial drug suspensions: a blinded comparison of taste of twelve common pediatric drugs including cefixime, cefpodoxime, cefprozil and loracarbef. [1994.02]
Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef. [1994.02]
Sputum and serum pharmacokinetics of loracarbef (LY163892) in patients with chronic bronchial sepsis. [1994.01]
Effect of loracarbef and amoxicillin on the oropharyngeal and intestinal microflora of patients with bronchitis. [1994]
Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. [1993.05]
Loracarbef: a new orally administered carbacephem antibiotic. [1993.03]
Pharmacokinetics of loracarbef in pediatric patients. [1992.07]
In vitro activity of loracarbef and effects of susceptibility test methods. [1992.06.22]
The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections. [1992.06.22]
Pharmacokinetic profile of loracarbef. [1992.06.22]
Effect of loracarbef on the normal oropharyngeal and intestinal microflora. [1991]
Loracarbef concentrations in middle ear fluid. [1990.10]
Other possibly related research studies
A critical review of the new oral cephalosporins. Considerations and place in therapy. [1994.11]
Haemophilus influenzae infection of human respiratory mucosa in low concentrations of antibiotics. [1993.07]
Pharmacokinetics of new oral cephalosporins, including a new carbacephem. [1993.05]
New antibacterial agents. [1993.01]
Antibiotic therapy for urinary tract infections. [1992.06.22]
Acute bronchitis: results of U.S. and European trials of antibiotic therapy. [1992.06.22]
The carbacephems: a new beta-lactam antibiotic class. [1992.06.22]
In vitro and in vivo antibacterial activity of KT3777, a new orally active carbacephem. [1989.12]
In-vitro activity and beta-lactamase stability of LY163892. [1988.08]
In vitro activity and beta-lactamase stability of LY163892. [1988.08]
Staphylococcal skin infections in children: rational drug therapy recommendations. [2005]
Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. [2004]
[Sensitivity of Haemophilus influenzae isolates in Spain to 17 oral antibiotics] [2003.03]
The fecal microflora of 1-3-month-old infants during treatment with eight oral antibiotics. [2002.06]
Patient, physician, and nurse satisfaction with antibiotics. [2002.06]
Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. [2001.01]
Compliance issues related to the selection of antibiotic suspensions for children. [2001.01]
Severe thrombocytopenia associated with alatrofloxacin. [2000.03]
[Pneumococcus observatory data in the Rhone-Alps region. Results from 1996] [1999.12]
Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. [1999.08]
Laboratory surveillance of Shigella dysenteriae type 1 in KwaZulu-Natal. [1999.01]
Otitis media: focus on antimicrobial resistance and new treatment options. [1998.09.15]
Strategies for the in vitro evolution of protein function: enzyme evolution by random recombination of improved sequences. [1997.09.26]
Antimicrobial treatment in acute maxillary sinusitis: a meta-analysis. [1997.08]
A double-blind taste comparison of pediatric antibiotic suspensions. [1997.04]
A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. [1997.03]
Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. [1997.02]
Optimizing industrial enzymes by directed evolution. [1997]
Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. [1996.12]
Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. [1996.09]
A multicenter, double blind comparison of azithromycin and amoxicillin/ clavulanate for the treatment of acute otitis media in children. [1996.09]
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. [1996.05]
Directed evolution of a para-nitrobenzyl esterase for aqueous-organic solvents. [1996.04]
Resistance among problem respiratory pathogens in pediatrics. [1995.05]
Oral cephalosporins: newer agents and their place in therapy. [1994.08]
[Peroral preparations of cephalosporin antibiotics] [1994.01.03]
Comparative pharmacokinetics of the new oral cephalosporins. [1994]
The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. [1992.09]
Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases. [1991.01]
[Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins] [1990]
|
